Getagraph.com logo
S&P 500 Futures
(1.14%) 5 149.50 points
Dow Jones Futures
(1.27%) 38 870 points
Nasdaq Futures
(1.59%) 17 931 points
Oil
(0.34%) $79.22
Gas
(0.10%) $2.04
Gold
(0.40%) $2 318.80
Silver
(0.32%) $26.92
Platinum
(1.16%) $973.80
USD/EUR
(-0.52%) $0.927
USD/NOK
(-1.24%) $10.86
USD/GBP
(-0.47%) $0.794
USD/RUB
(0.52%) $91.61

Realaus laiko atnaujinimai CEL-SCI Corp [CVM]

Birža: AMEX Pramonė: Biotechnology
Atnaujinta2 geg. 2024 @ 23:00
25% discount on Stockinvest.us - Use code: Podcast

4.23% $ 1.480

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer...

Stats
Šios dienos apimtis 133 298
Vidutinė apimtis 302 678
Rinkos kapitalizacija 79.89M
EPS $0 ( 2024-02-13 )
Kita pelno data ( $-0.140 ) 2024-05-10
Last Dividend $0.250 ( 1996-08-28 )
Next Dividend $0 ( N/A )
P/E -2.14
ATR14 $0.00600 (0.40%)
Insider Trading
Date Person Action Amount type
2024-04-19 Gobbo Mario Sell 0 Common Stock
2024-04-19 Gobbo Mario Sell 64 000 Options
2024-04-19 Watson Robert Eugene Buy 64 000 Options
2024-04-19 Baillavoine Bruno Jean-marie Buy 64 000 Options
2024-04-19 Talor Eyal Buy 182 000 Options
INSIDER POWER
90.70
Last 100 transactions
Buy: 5 618 116 | Sell: 153 000

Tūris Koreliacija

Ilgas: 0.30 (neutral)
Trumpas: 0.47 (neutral)
Signal:(59.008) Neutral

CEL-SCI Corp Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

CEL-SCI Corp Koreliacija - Valiuta/Žaliavos

The country flag 0.54
( weak )
The country flag 0.85
( strong )
The country flag 0.00
( neutral )
The country flag 0.46
( neutral )
The country flag 0.00
( neutral )
The country flag -0.74
( moderate negative )

CEL-SCI Corp Finansinės ataskaitos

Annual 2023
Pajamos: $0
Bruto pelnas: $-3.96M (0.00 %)
EPS: $-0.720
FY 2023
Pajamos: $0
Bruto pelnas: $-3.96M (0.00 %)
EPS: $-0.720
FY 2022
Pajamos: $0
Bruto pelnas: $-3.88M (0.00 %)
EPS: $-0.890
FY 2021
Pajamos: $0.00
Bruto pelnas: $0.00 (0.00 %)
EPS: $-0.900

Financial Reports:

No articles found.

CEL-SCI Corp Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A)

CEL-SCI Corp Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A
Information
First Dividend $0.250 1996-08-28
Last Dividend $0.250 1996-08-28
Next Dividend $0 N/A
Payout Date 2017-06-15
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.250 --
Avg. Dividend % Per Year 0.00% --
Score 0.01 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
 (2024-05-03)
$0 Estimate 0.00 %
Dividend Stability
0.00 Very Bad
Dividend Score
0.01
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for AMEX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
RIET Ex Dividend Junior 2023-09-12 Monthly 0 0.00%
AE Ex Dividend Knight 2023-09-07 Quarterly 0 0.00%
EAD Ex Dividend King 2023-09-11 Monthly 0 0.00%
JIB Ex Dividend Junior 2023-09-01 Bi-Monthly 0 0.00%
PFRL Ex Dividend Junior 2023-08-01 Monthly 0 0.00%
DFAR Ex Dividend Knight 2023-09-19 Quarterly 0 0.00%
HWM-P Ex Dividend Knight 2023-09-07 Annually 0 0.00%
CLM Ex Dividend Knight 2023-10-13 Monthly 0 0.00%
GLO Ex Dividend Knight 2023-09-21 Monthly 0 0.00%
NOG Ex Dividend Knight 2023-09-27 Quarterly 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM01.50000[0 - 0.5]
returnOnAssetsTTM-1.0871.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-2.051.500-10.00-10.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM1.2640.8008.686.94[1 - 3]
quickRatioTTM0.1840.800-3.62-2.90[0.8 - 2.5]
cashRatioTTM0.6661.5007.4110.00[0.2 - 2]
debtRatioTTM0.456-1.5002.40-3.59[0 - 0.6]
interestCoverageTTM-42.081.000-10.00-10.00[3 - 30]
operatingCashFlowPerShareTTM-0.4762.00-0.159-0.317[0 - 30]
freeCashFlowPerShareTTM-0.4842.00-0.242-0.484[0 - 20]
debtEquityRatioTTM1.035-1.5005.86-8.79[0 - 2.5]
grossProfitMarginTTM01.000-3.33-3.33[0.2 - 0.8]
operatingProfitMarginTTM01.000-2.00-2.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-1.7611.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score-2.64

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-2.301.000-0.3330[1 - 100]
returnOnEquityTTM-2.052.50-10.00-10.00[0.1 - 1.5]
freeCashFlowPerShareTTM-0.4842.00-0.161-0.484[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.4762.00-0.159-0.317[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-0.04591.500-3.640[0.5 - 2]
operatingCashFlowSalesRatioTTM01.000-2.500[0.1 - 0.5]
Total Score-1.893

CEL-SCI Corp

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.